Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864

Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families

Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268

Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology

Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028

TREM2 Variants in Alzheimer's Disease

Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020

Variant of TREM2 Associated with the Risk of Alzheimer's Disease

Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516

Chronic traumatic encephalopathy in athletes: Progressive tauopathy after repetitive head injury

McKee, A. C., Cantu, R. C., Nowinski, C. J., Hedley-Whyte, E. T., Gavett, B. E., Budson, A. E., Santini, V. E., Lee, H.-S., Kubilus, C. A., & Stern, R. A. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181a9d503 · Cited by 2,295

Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E

Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204

Alzheimer disease

Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606

Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways

Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0281-2 · Cited by 947

Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight

Shi, Y., & Holtzman, D. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0051-1 · Cited by 595

Bidirectional relationship between sleep and Alzheimer’s disease: role of amyloid, tau, and other factors

Wang, C., & Holtzman, D. M. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0478-5 · Cited by 615

A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward

Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570

Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease

Depp, C., Sun, T., Sasmita, A. O., Spieth, L., Berghoff, S. A., Nazarenko, T., Overhoff, K., Steixner-Kumar, A. A., Subramanian, S., Arinrad, S., et al. (2023) · Nature · doi:10.1038/s41586-023-06120-6 · Cited by 493

ApoE4: an emerging therapeutic target for Alzheimer’s disease

Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449

Dementia in Down syndrome: unique insights for Alzheimer disease research

Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383

APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer’s disease patient iPSC-derived cerebral organoids

Zhao, J., Fu, Y., Yamazaki, Y., Ren, Y., Davis, M. D., Liu, C.-C., Lu, W., Wang, X., Chen, K., Cherukuri, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19264-0 · Cited by 374

Alzheimer’s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs

Monteiro, A. R., Barbosa, D. J., Remião, F., & Silva, R. V. D. S. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115522 · Cited by 375

ApoE facilitates the microglial response to amyloid plaque pathology

Ulrich, J. D., Ulland, T. K., Mahan, T. E., Nyström, S., Nilsson, K. P., Song, W. M., Zhou, Y., Reinartz, M., Choi, S., Jiang, H., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171265 · Cited by 297

Emerging roles of innate and adaptive immunity in Alzheimer’s disease

Chen, X., & Holtzman, D. M. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.016 · Cited by 297

Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials

Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293

APOE mediated neuroinflammation and neurodegeneration in Alzheimer’s disease

Parhizkar, S., & Holtzman, D. M. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101594 · Cited by 255

Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology

Rahman, M. M., & Lendel, C. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00465-0 · Cited by 260

Apolipoprotein E and Alzheimer’s disease: Findings, hypotheses, and potential mechanisms

Koutsodendris, N., Nelson, M. R., Rao, A., & Huang, Y. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-030421-112756 · Cited by 231

Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer’s Disease

Lewcock, J. W., Schlepckow, K., Di Paolo, G., Tahirovic, S., Monroe, K. M., & Haass, C. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.029 · Cited by 221

APOE and Alzheimer’s Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer’s Pathogenesis

Uddin, M. S., Kabir, M. T., Al Mamun, A., Abdel-Daim, M. M., Barreto, G. E., & Ashraf, G. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1237-z · Cited by 212

Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis

Huynh, T.-P. V., Liao, F., Francis, C. M., Robinson, G. O., Serrano, J. R., Jiang, H., Roh, J., Finn, M. B., Sullivan, P. M., Esparza, T. J., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.014 · Cited by 209

A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment

Das, B., & Yan, R. (2019) · CNS Drugs · doi:10.1007/s40263-019-00613-7 · Cited by 218

APOE4 derived from astrocytes leads to blood–brain barrier impairment

Jackson, R. J., Meltzer, J. C., Nguyen, H., Commins, C., Bennett, R. E., Hudry, E., & Hyman, B. T. (2022) · Brain · doi:10.1093/brain/awab478 · Cited by 205

Mechanisms underlying the pathophysiology of type 2 diabetes: From risk factors to oxidative stress, metabolic dysfunction, and hyperglycemia

Lima, J. E. B. F., Moreira, N. C. S., & Sakamoto-Hojo, E. T. (2022) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2021.503437 · Cited by 203

APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer’s mice via cyclophilin A independently of amyloid-β

Montagne, A., Nikolakopoulou, A. M., Huuskonen, M. T., Sagare, A. P., Lawson, E. J., Lazic, D., Rege, S. V., Grond, A., Zuniga, E., Barnes, S. R., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00073-z · Cited by 188

Understanding the Amyloid Hypothesis in Alzheimer’s Disease

Paroni, G., Bisceglia, P., & Seripa, D. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180802 · Cited by 194

Neuronal ROS-Induced Glial Lipid Droplet Formation is Altered by Loss of Alzheimer's Disease-Associated Genes

Moulton, M. J., Barish, S., Ralhan, I., Chang, J., Goodman, L. D., Harland, J. G., Marcogliese, P. C., Johansson, J. O., Ioannou, M. S., & Bellen, H. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2112095118 · Cited by 180

Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation

Liao, F., Li, A., Xiong, M., Bien-Ly, N., Jiang, H., Zhang, Y., Finn, M. B., Hoyle, R., Keyser, J., Lefton, K. B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96429 · Cited by 178

APOE genotype regulates pathology and disease progression in synucleinopathy

Davis, A. A., Inman, C. E., Wargel, Z. M., Dube, U., Freeberg, B. M., Galluppi, A., Haines, J. N., Dhavale, D. D., Miller, R., Choudhury, F. A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay3069 · Cited by 177

Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype

Mishra, S., Blazey, T. M., Holtzman, D. M., Cruchaga, C., Su, Y., Morris, J. C., Benzinger, T. L. S., & Gordon, B. A. (2018) · Brain · doi:10.1093/brain/awy103 · Cited by 151

Apolipoprotein E and Alzheimer's disease

Troutwine, B., Hamid, L., Lysaker, C. R., Strope, T. A., & Wilkins, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.002 · Cited by 179

Cellular cholesterol homeostasis and Alzheimer’s disease

Chang, T.-Y., Yamauchi, Y., Hasan, M. T., & Chang, C. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075630 · Cited by 155

Invited Review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer's disease

Tzioras, M., Davies, C., Newman, A., Jackson, R., & Spires‐Jones, T. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12529 · Cited by 147

Microglial activation states and their implications for Alzheimer's Disease

Valiukas, Z., Tangalakis, K., Apostolopoulos, V., & Feehan, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100013 · Cited by 167

The endosomal-lysosomal pathway is dysregulated by APOE4 expression in vivo

Nuriel, T., Peng, K. Y., Ashok, A., Dillman, A. A., Figueroa, H. Y., Apuzzo, J., Ambat, J., Levy, E., Cookson, M. R., Mathews, P. M., et al. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00702 · Cited by 140

Decoding microglial immunometabolism: a new frontier in Alzheimer's disease research

Jung, E. S., Choi, H., & Mook-Jung, I. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00825-0 · Cited by 124

APOE-amyloid interaction: Therapeutic targets

Wisniewski, T., & Drummond, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104784 · Cited by 131

Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview

Bilal, M., Barani, M., Sabir, F., Rahdar, A., & Kyzas, G. Z. (2020) · NanoImpact · doi:10.1016/j.impact.2020.100251 · Cited by 131

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease

Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125

25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner

Wong, M. Y., Lewis, M., Doherty, J. J., Shi, Y., Cashikar, A. G., Amelianchik, A., Tymchuk, S., Sullivan, P. M., Qian, M., Covey, D. F., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01869-3 · Cited by 121

Amyloid-β oligomers in cellular models of Alzheimer’s disease

Fontana, I. C., Zimmer, A. R., Rocha, A. S., Gosmann, G., Souza, D. O., Lourenco, M. V., Ferreira, S. T., & Zimmer, E. R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15030 · Cited by 115

Humanising the mouse genome piece by piece

Zhu, F., Nair, R., Fisher, E., & Cunningham, T. J. (2019) · Nature Communications · doi:10.1038/s41467-019-09716-7 · Cited by 114

Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer’s Pathogenesis

Penke, B., Szűcs, M., & Bogár, F. (2020) · Molecules · doi:10.3390/molecules25071659 · Cited by 119

Apolipoprotein E in Alzheimer’s disease: molecular insights and therapeutic opportunities

Belaidi, A. A., Bush, A. I., & Ayton, S. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00843-y · Cited by 91

β‐Amyloid aggregation and heterogeneous nucleation

Srivastava, A. K., Pittman, J. M., Zerweck, J., Venkata, B. S., Moore, P. C., Sachleben, J. R., & Meredith, S. C. (2019) · Protein Science · doi:10.1002/pro.3674 · Cited by 82

Endo-lysosomal pathway and ubiquitin-proteasome system dysfunction in Alzheimer's disease pathogenesis

Cao, J., Zhong, M. B., Toro, C. A., Zhang, L., & Cai, D. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.03.016 · Cited by 82

Hidden heterogeneity in Alzheimer's disease: Insights from genetic association studies and other analyses

Yashin, A. I., Fang, F., Kovtun, M., Wu, D., Duan, M., Arbeev, K. G., Akushevich, I. V., Kulminski, A. M., Culminskaya, I. V., Zhbannikov, I. Y., et al. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2017.10.020 · Cited by 72

MicroRNA in Alzheimer’s disease revisited: implications for major neuropathological mechanisms

Dehghani, R., Rahmani, F., & Rezaei, N. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0042 · Cited by 72

Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease

Xia, Z., Prescott, E. E., Urbanek, A., Wareing, H. E., King, M. C., Olerinyova, A., Dakin, H., Leah, T., Barnes, K. A., Matuszyk, M. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49028-z · Cited by 67

Alzheimer's disease and symbiotic microbiota: an evolutionary medicine perspective

Fox, M. M., Knorr, D. A., & Haptonstall, K. P. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14129 · Cited by 67

Murine Gut Microbiome Association With APOE Alleles

Parikh, I. J., Estus, J. L., Zajac, D. J., Malik, M., Weng, J. M., Tai, L. M., Chlipala, G. E., LaDu, M. J., Green, S. J., & Estus, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00200 · Cited by 64

Transcriptional Effects of ApoE4: Relevance to Alzheimer’s Disease

Theendakara, V., Peters-Libeu, C. A., Bredesen, D. E., & Rao, R. V. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0757-2 · Cited by 63

α-synuclein−lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients

Pasławski, W., Zarȩba-Pasławska, J., Zhang, X., Hölzl, K., Wadensten, H., Shariatgorji, M., Janelidze, S., Hansson, O., Forsgren, L., Andrén, P. E., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821409116 · Cited by 62

Transitions in metabolic and immune systems from pre-menopause to post-menopause: implications for age-associated neurodegenerative diseases

Wang, Y., Mishra, A., & Brinton, R. D. (2020) · F1000Research · doi:10.12688/f1000research.21599.1 · Cited by 65

RAB10: an Alzheimer’s disease resilience locus and potential drug target

Tavana, J., Rosene, M., Jensen, N., Ridge, P. G., Kauwe, J. S. K., & Karch, C. M. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s159148 · Cited by 62

Apolipoprotein E4 Expression Causes Gain of Toxic Function in Isogenic Human Induced Pluripotent Stem Cell-Derived Endothelial Cells

Rieker, C., Migliavacca, E., Vaucher, A., Mayer, F. C., Baud, G., Marquis, J., Charpagne, A., Hegde, N., Guignard, L., McLachlan, M. J., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312261 · Cited by 59

Targeting Apolipoprotein E/Amyloid β Binding by Peptoid CPO_Aβ17-21 P Ameliorates Alzheimer’s Disease Related Pathology and Cognitive Decline

Liu, S., Park, S.-A., Allington, G., Prelli, F., Sun, Y., Martá-Ariza, M., Scholtzova, H., Biswas, G. K., Brown, B., Verghese, P. B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08604-8 · Cited by 58

Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease

Kulas, J. A., Weigel, T. K., & Ferris, H. A. (2020) · Drug Development Research · doi:10.1002/ddr.21643 · Cited by 57

Key Peptides and Proteins in Alzheimer’s Disease

Penke, B., Bogár, F., Paragi, G., Gera, J., & Fülöp, L. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190103123434 · Cited by 51

Phagocytosis of Apoptotic Cells Is Specifically Upregulated in ApoE4 Expressing Microglia in vitro

Muth, C., Hartmann, A., Falla, D. S., Glatzel, M., & Krasemann, S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00181 · Cited by 47

Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care

Knopman, D. S., & Hershey, L. A. (2023) · Neurology · doi:10.1212/wnl.0000000000207438 · Cited by 47

Selenium-containing compounds: a new hope for innovative treatments in Alzheimer’s disease and Parkinson’s disease

Pyka, P., Garbo, S., Fioravanti, R., Jacob, C., Hittinger, M., Handzlik, J., Zwergel, C., & Battistelli, C. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104062 · Cited by 48

Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease

Theendakara, V. P., Bredesen, D. E., & Rao, R. V. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.07.002 · Cited by 45

NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load

Pohlkamp, T., Xian, X., Wong, C. H., Durakoglugil, M. S., Werthmann, G. C., Saido, T. C., Evers, B. M., White, C. L., Connor, J., Hammer, R. E., et al. (2021) · eLife · doi:10.7554/elife.72034 · Cited by 46

Role of TREM2 in Alzheimer's Disease and its Consequences on β- Amyloid, Tau and Neurofibrillary Tangles

Singh, A. K., Mishra, G., Maurya, A., Awasthi, R., Kumari, K., Thakur, A., Rai, A., Rai, G. K., Sharma, B., Kulkarni, G. T., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190903102822 · Cited by 45

APOE 𝜀4‐related blood–brain barrier breakdown is associated with microstructural abnormalities

Reas, E. T., Solders, S. K., Tsiknia, A. A., Triebswetter, C., Shen, Q., Rivera, C. S., Andrews, M., Alderson‐Myers, A., & Brewer, J. B. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14302 · Cited by 45

Recent advancements toward therapeutic vaccines against Alzheimer’s disease

Herline, K., Drummond, E., & Wısnıewskı, T. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1500905 · Cited by 46

Apolipoprotein E and clusterin inhibit the early phase of amyloid-β aggregation in an in vitro model of cerebral amyloid angiopathy

Endo, Y., Hasegawa, K., Nomura, R., Arishima, H., Kikuta, K., Yamashita, T., Inoue, Y., Ueda, M., Ando, Y., Wilson, M. R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0662-1 · Cited by 42

Lipid-Binding Proteins in Brain Health and Disease

Corraliza-Gómez, M., Sánchez, D., & Ganfornina, M. D. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01152 · Cited by 43

Multi-target approach to Alzheimer’s disease prevention and treatment: antioxidant, anti-inflammatory, and amyloid- modulating mechanisms

Abbas, K., Mustafa, M., Alam, M., Habib, S., Ahmad, W., Adnan, M., Hassan, M. I., & Usmani, N. (2025) · Neurogenetics · doi:10.1007/s10048-025-00821-y · Cited by 48

High‐affinity multivalent interactions between apolipoprotein E and the oligomers of amyloid‐β

Ghosh, S., Sil, T. B., Dolai, S., & Garai, K. (2019) · FEBS Journal · doi:10.1111/febs.14988 · Cited by 40

The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimer’s Disease

Chernick, D., Zhong, R., & Li, L. (2020) · Biomolecules · doi:10.3390/biom10091276 · Cited by 39

Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid-β

Chai, A. B., Lam, H. H. J., Kockx, M., & Gelissen, I. C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158980 · Cited by 41

Modeling Alzheimer’s disease with human iPS cells: advancements, lessons, and applications

Essayan-Perez, S., Zhou, B., Nabet, A. M., Wernig, M., & Huang, Y. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104503 · Cited by 40

Identifying Vulnerable Brain Networks in Mouse Models of Genetic Risk Factors for Late Onset Alzheimer’s Disease

Badea, A., Wu, W., Shuff, J., Wang, M. S., Anderson, R. J., Qi, Y. P., Johnson, G. A., Wilson, J. G., Koudoro, S., Garyfallidis, E., et al. (2019) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2019.00072 · Cited by 31

The relationship between hypoxia and Alzheimer’s disease: an updated review

Tao, B., Gong, W., Xu, C., Ma, Z., Mei, J., & Chen, M. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1402774 · Cited by 36

Alzheimer’s Disease (AD) Therapeutics—2: Beyond Amyloid—Re-Defining AD and Its Causality to Discover Effective Therapeutics

Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32

Genetic mutations of APOEε4 carriers in cardiovascular patients lead to the development of insulin resistance and risk of Alzheimer's disease

Jabeen, K., Rehman, K., & Akash, M. S. H. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22953 · Cited by 31

Toward the Language Oscillogenome

Murphy, E., & Benítez‐Burraco, A. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01999 · Cited by 30

Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer’s Disease Sequencing Project

Blue, E., Bis, J. C., Dorschner, M. O., Tsuang, D. W., Barral, S., Beecham, G. W., Below, J. E., Bush, W. S., Butkiewicz, M., Cruchaga, C., et al. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000485503 · Cited by 30

Effects of DDT on Amyloid Precursor Protein Levels and Amyloid Beta Pathology: Mechanistic Links to Alzheimer’s Disease Risk

Eid, A., Mhatre‐Winters, I., Sammoura, F. M., Edler, M. K., von Stein, R., Hossain, M. M., Han, Y., Lisci, M., Carney, K., Konsolaki, M., et al. (2022) · Environmental Health Perspectives · doi:10.1289/ehp10576 · Cited by 31

Diversity in Aβ deposit morphology and secondary proteome insolubility across models of Alzheimer-type amyloidosis

Xu, G. M., Fromholt, S., Chakrabarty, P., Zhu, F., Liu, X., Pace, M. C., Koh, J., Golde, T. E., Levites, Y., Lewis, J. M., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00911-y · Cited by 29

The amyloid state of proteins: A boon or bane?

Hassan, M. N., Nabi, F., Khan, A. N., Hussain, M. S., Siddiqui, W. A., Uversky, V. N., & Khan, R. H. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.01.115 · Cited by 30

Recent Progress in Research on Mechanisms of Action of Natural Products against Alzheimer’s Disease: Dietary Plant Polyphenols

Wang, Y., Wang, K., Yan, J., Zhou, Q., & Wang, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213886 · Cited by 32

ApoE isoforms and carboxyl-terminal-truncated apoE4 forms affect neuronal BACE1 levels and Aβ production independently of their cholesterol efflux capacity

Dafnis, I., Raftopoulou, C., Mountaki, C., Megalou, E. V., Zannis, V. I., & Chroni, A. (2018) · Biochemical Journal · doi:10.1042/bcj20180068 · Cited by 29

Cholesterol and matrisome pathways dysregulated in human APOE ε4 gliaPreprint

Julia, T. C. W., Liang, S., Lü, Q., Pipalia, N. H., Chao, M. J., Shi, Y., Bertelsen, S. E., Kapoor, M., Marcora, E. M., Sikora, E., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/713362 · Cited by 29

Cerebrospinal fluid neurogranin/β‐site APP‐cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease

Kirsebom, B., Nordengen, K., Selnes, P., Waterloo, K. K., Torsetnes, S. B., Gísladóttir, B., Brix, B., Vanmechelen, E., Bråthen, G., Hessen, E., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.003 · Cited by 27

How does apolipoprotein E genotype influence the relationship between physical activity and Alzheimer’s disease risk? A novel integrative model

de Frutos‐Lucas, J., Sewell, K. R., García‐Colomo, A., Markovic, S. J., Erickson, K. I., & Brown, B. M. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01170-4 · Cited by 26

Potential Novel Approaches to Understand the Pathogenesis and Treat Alzheimer’s Disease

Drummond, E., Goñi, F., Liu, S., Prelli, F., Scholtzova, H., & Wısnıewskı, T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179909 · Cited by 26

Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk

Zhou, Y., Mägi, R., Milani, L. A., & Lauschke, V. M. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p086710 · Cited by 28

Sex and APOE Genotype Alter the Basal and Induced Inflammatory States of Primary Microglia from APOE Targeted Replacement Mice

Mhatre‐Winters, I., Eid, A., Han, Y., Tieu, K., & Richardson, J. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179829 · Cited by 26

Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?

Vecchio, F. L., Bisceglia, P., Imbimbo, B. P., Lozupone, M., Latino, R. R., Resta, E., Leone, M., Solfrizzi, V., Greco, A., Daniele, A., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221081605 · Cited by 28

Human apolipoprotein E isoforms are differentially sialylated and the sialic acid moiety in ApoE2 attenuates ApoE2-Aβ interaction and Aβ fibrillation

Moon, H.-J., Haroutunian, V., & Zhao, L. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105631 · Cited by 25

Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases

Loch, R. A., Wang, H., Perálvarez‐Marín, A., Berger, P., Nielsen, H. M., Chroni, A., & Luo, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.01.022 · Cited by 26

Cerebrospinal fluid neutral lipids predict progression from mild cognitive impairment to Alzheimer’s disease

Dakterzada, F., Jové, M., Huerto, R. P., Carnes, A., Sol, J., Pamplona, R., & Piñol‐Ripoll, G. (2023) · GeroScience · doi:10.1007/s11357-023-00989-x · Cited by 27

Transmissible Endosomal Intoxication: A Balance between Exosomes and Lysosomes at the Basis of Intercellular Amyloid Propagation

Bécot, A., Volgers, C., & van Niel, G. (2020) · Biomedicines · doi:10.3390/biomedicines8080272 · Cited by 25

Nanoparticle–proteome in vitro and in vivo

Wang, M., Gustafsson, O., Pilkington, E. H., Käkinen, A., Javed, I., Faridi, A., Davis, T. P., & Ke, P. C. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb01634h · Cited by 23

The E3 ubiquitin ligase inducible degrader of the LDL receptor/myosin light chain interacting protein in health and disease

van Loon, N. M., Lindholm, D., & Zelcer, N. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000593 · Cited by 25

Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer’s disease cognition

Johnson, N. R., Wang, A. C.-J., Coughlan, C. M., Sillau, S., Lucero, E., Viltz, L., Markham, N. E., Allen, C., Dhanasekaran, A. R., Chial, H. J., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01020-9 · Cited by 24

Retinoic Acid and the Gut Microbiota in Alzheimer’s Disease: Fighting Back-to-Back?

Endres, K. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163705 · Cited by 22

Updated Outlook of Cerebral Amyloid Angiopathy and Inflammatory Subtypes: Pathophysiology, Clinical Manifestations, Diagnosis and Management

Singh, B., Lavezo, J., Gavito-Higuera, J., Ahmed, F., Narasimhan, S. S., Brar, S. K., Cruz‐Flores, S., & Kraus, J. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220055 · Cited by 24

[PL2‐01]: Apolipoprotein E, Alzheimer's disease and cerebral amyloid angiopathy: Effects of apoE on amyloid‐B metabolism suggest underlying mechanisms and potential treatments

Holtzman, D. M. (2005) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.06.316

Apolipoprotein E in Alzheimer’s disease: molecular insights and therapeutic opportunities

Belaidi, A. A., Bush, A. I., & Ayton, S. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00843-y · Cited by 91

Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E

Liao, F., & Holtzman, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00010-1

Role of Apolipoprotein E in Alzheimer's Disease Pathogenesis, Prognosis and Treatment

Reiss, A. B., Housny, M., Gulkarov, S., Hossain, T., Locke, B., Srivastava, A., Pinkhasov, A., Gomolin, I. H., Wısnıewskı, T., & Leon, J. D. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436189.179 · Cited by 11

Apolipoprotein E, Receptors, and Modulation of Alzheimer’s Disease

Zhao, N., Liu, C.-C., Qiao, W., & Bu, G. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.003 · Cited by 370